BioAtla Investor Presentation Deck

Broad applicability of BioAtla's CAB platform across several antibody types has the potential to treat multiple solid tumors Targets: AXL, ROR2 ADCs Widely expressed in a variety of tumor types, AXL and ROR2 overexpression correlates with poor prognosis, metastasis, and drug resistance to PD-1 and EGFR therapies CAB-Tumor Cell Target bicatla Cytotoxic payload and linker Naked Antibodies I/O ADC - antibody drug conjugate; 10 - immuno-oncology; TCE - T-cell engager Target: CTLA-4 CTLA-4 blockade activates effector T cells, thereby enhancing anti- tumor immunity CAB-CTLA4 CAB-CTLA4 Bispecific TCE Target: EpCAM & CD3 Bispecific antibodies bridge cancer cells and cytotoxic T lymphocytes, activating T cells and promoting cancer cell lysis Tumor Cell Target T Cell Target CAB-EPCAM CAB-CD3 BioAtla| Overview 7

View entire presentation